BioCentury | Aug 30, 2019
Politics & Policy

Industry group responds to Dutch Minister’s 'something’s gotta give' reaction to drug price increases

...price hike in the last two years could fit Bruins' description. Chenodiol chenodeoxycholic acid from Leadiant Biosciences S.p.A....
...estimated total cost of €11.1 million ($12.2 million) for 2019, or €163,000 ($178,949) per patient. Leadiant...
...production is limited to small batches and is used by patients affiliated with the pharmacy. Leadiant’s...
BioCentury | Jan 12, 2019
Finance

We all fall down

...treat relapsed or refractory mycosis fungoides or Sézary syndrome, types of cutaneous T cell lymphoma Leadiant Biosciences S.p.A....
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Oct 26, 2018
Clinical News

Leadiant gets Priority Review voucher

...a Priority Review voucher to Leadiant Biosciences Inc. The voucher was issued after FDA approved Leadiant's...
...to treat pediatric and adult patients with adenosine deaminase severe combined immunodeficiency (see "FDA Approves Leadiant...
...of Leadiant Biosciences S.p.A. (Rome, Italy). Leadiant Biosciences S.p.A., Rome, Italy Product: Revcovi elapegademase-lvlr (EZN-2279) Business: Endocrine/Metabolic Chris Lieu Revcovi, elapegademase (EZN-2279) Leadiant Biosciences S.p.A. Metabolic...
BioCentury | Oct 12, 2018
Clinical News

FDA approves Leadiant therapy for ADA-SCID

...lymphocyte counts and led to metabolite detoxification in 10 patients with ADA-SCID undergoing treatment with Leadiant's...
...receiving Revcovi. Leadiant expects to deliver an interim report to FDA in 2021. Minarich said Leadiant...
...subsidiary of Leadiant Biosciences S.p.A. (Rome, Italy). Leadiant Biosciences S.p.A., Rome, Italy Product: Revcovi elapegademase-lvlr (EZN-2279) Business: Endocrine/Metabolic Mary Romeo Elapegademase (EZN-2279) Leadiant Biosciences S.p.A. Adenosine...
BioCentury | Oct 8, 2018
Company News

FDA approves Leadiant therapy for ADA-SCID

...lymphocyte counts and led to metabolite detoxification in 10 patients with ADA-SCID undergoing treatment with Leadiant's...
...receiving Revcovi. Leadiant expects to deliver an interim report to FDA in 2021. Minarich said Leadiant...
...the U.S. subsidiary of Leadiant Biosciences S.p.A. (Rome, Italy). Mary Romeo Adagen (Brand), adenosine deaminase (Generic), PEG-adenosine deaminase (Informal) Elapegademase (EZN-2279) Leadiant Biosciences S.p.A....
BioCentury | Jun 13, 2018
Distillery Therapeutics

Cancer

...liver metastases. Next steps could include testing other primary bile acids in liver tumor models. Leadiant Biosciences S.p.A....
BioCentury | Apr 17, 2018
Distillery Therapeutics

Ophthalmic disease

...THR-149, a KLKB1 inhibitor of undisclosed type, in preclinical testing for macular edema. Shire plc, Leadiant Biosciences S.p.A....
BioCentury | May 9, 2017
Politics & Policy

PhRMA revises eligibility criteria, cutting membership

...NASDAQ:JAZZ), Mallinckrodt plc (NYSE:MNK), Orexigen Therapeutics Inc. (NASDAQ:OREX) and The Medicines Co. (NASDAQ:MDCO). The seventh, Leadiant...
...BioCentury Extra, Feb. 18) . Becky Simon AMAG Pharmaceuticals Inc. BioMarin Pharmaceutical Inc. Esperion Therapeutics Inc. Horizon Pharma plc Jazz Pharmaceuticals plc Leadiant Biosciences S.p.A. Mallinckrodt...
Items per page:
1 - 9 of 9
BioCentury | Aug 30, 2019
Politics & Policy

Industry group responds to Dutch Minister’s 'something’s gotta give' reaction to drug price increases

...price hike in the last two years could fit Bruins' description. Chenodiol chenodeoxycholic acid from Leadiant Biosciences S.p.A....
...estimated total cost of €11.1 million ($12.2 million) for 2019, or €163,000 ($178,949) per patient. Leadiant...
...production is limited to small batches and is used by patients affiliated with the pharmacy. Leadiant’s...
BioCentury | Jan 12, 2019
Finance

We all fall down

...treat relapsed or refractory mycosis fungoides or Sézary syndrome, types of cutaneous T cell lymphoma Leadiant Biosciences S.p.A....
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Oct 26, 2018
Clinical News

Leadiant gets Priority Review voucher

...a Priority Review voucher to Leadiant Biosciences Inc. The voucher was issued after FDA approved Leadiant's...
...to treat pediatric and adult patients with adenosine deaminase severe combined immunodeficiency (see "FDA Approves Leadiant...
...of Leadiant Biosciences S.p.A. (Rome, Italy). Leadiant Biosciences S.p.A., Rome, Italy Product: Revcovi elapegademase-lvlr (EZN-2279) Business: Endocrine/Metabolic Chris Lieu Revcovi, elapegademase (EZN-2279) Leadiant Biosciences S.p.A. Metabolic...
BioCentury | Oct 12, 2018
Clinical News

FDA approves Leadiant therapy for ADA-SCID

...lymphocyte counts and led to metabolite detoxification in 10 patients with ADA-SCID undergoing treatment with Leadiant's...
...receiving Revcovi. Leadiant expects to deliver an interim report to FDA in 2021. Minarich said Leadiant...
...subsidiary of Leadiant Biosciences S.p.A. (Rome, Italy). Leadiant Biosciences S.p.A., Rome, Italy Product: Revcovi elapegademase-lvlr (EZN-2279) Business: Endocrine/Metabolic Mary Romeo Elapegademase (EZN-2279) Leadiant Biosciences S.p.A. Adenosine...
BioCentury | Oct 8, 2018
Company News

FDA approves Leadiant therapy for ADA-SCID

...lymphocyte counts and led to metabolite detoxification in 10 patients with ADA-SCID undergoing treatment with Leadiant's...
...receiving Revcovi. Leadiant expects to deliver an interim report to FDA in 2021. Minarich said Leadiant...
...the U.S. subsidiary of Leadiant Biosciences S.p.A. (Rome, Italy). Mary Romeo Adagen (Brand), adenosine deaminase (Generic), PEG-adenosine deaminase (Informal) Elapegademase (EZN-2279) Leadiant Biosciences S.p.A....
BioCentury | Jun 13, 2018
Distillery Therapeutics

Cancer

...liver metastases. Next steps could include testing other primary bile acids in liver tumor models. Leadiant Biosciences S.p.A....
BioCentury | Apr 17, 2018
Distillery Therapeutics

Ophthalmic disease

...THR-149, a KLKB1 inhibitor of undisclosed type, in preclinical testing for macular edema. Shire plc, Leadiant Biosciences S.p.A....
BioCentury | May 9, 2017
Politics & Policy

PhRMA revises eligibility criteria, cutting membership

...NASDAQ:JAZZ), Mallinckrodt plc (NYSE:MNK), Orexigen Therapeutics Inc. (NASDAQ:OREX) and The Medicines Co. (NASDAQ:MDCO). The seventh, Leadiant...
...BioCentury Extra, Feb. 18) . Becky Simon AMAG Pharmaceuticals Inc. BioMarin Pharmaceutical Inc. Esperion Therapeutics Inc. Horizon Pharma plc Jazz Pharmaceuticals plc Leadiant Biosciences S.p.A. Mallinckrodt...
Items per page:
1 - 9 of 9